DELSOL Avocats is proud to be listed in 3 Chambers and Partners 2024 rankings : Corporate/M&A : Mid-Market - Band 3 Litigation : Highly Regarded - Band 3 General Business Law - Spotlight In addition to these collective rankings,Gaëlle MERLIER has been designated « Up and Coming » lawyer in « Pharma/Life Sciences : Product Liability » and...
Read- 14 mars 2024
- Henri-Louis DELSOL, Gaëlle MERLIER
- Mergers & Acquisitions - Corporate law, Civil and commercial litigation
- 12 mars 2024
- Charles PRICE
- Civil and commercial litigation
Charles Price participated as an arbitrator in the 2024 Brussels Pre Moot organized by White & Case and Linklaters in preparation for the 31st Willem C. Vis International Commercial Arbitration Moot to be held in Hong Kong on 10 -17 March and in Vienna on 22 - 28 March. 👉 Information and...
Read- 5 mars 2024
- Julien MONSENEGO, Jean-François DEFUDES
- Corporate taxation
Article 116 of the Finance Law for 2024, published in the Journal Officiel on December 30, 2023, confirmed measures with a substantial impact on transfer pricing. These evolutions are reflected in a reinforcement of the documentary obligations imposed on companies, but also in measures designed to reinforce audits by the tax authorities. In...
Read- 4 mars 2024
- Caroline DA LAGE, Jessica NEUFVILLE, Arnaud LAROCHE
- Mergers & Acquisitions - Corporate law, Employment law - Social welfare law, Non-profit organisations - Social and solidarity-based entrepreneurship
DELSOL Avocats is delighted to announce the promotion to Counsel status of three lawyers : Caroline Da Lage (Mergers & Acquisitions - Corporate Law), Jessica Neufville (Employment Law – Social welfare law, Distressed companies - Restructuring) and Arnaud Laroche (Non-profit Organisations - Social and solidarity-based entrepreneurship)....
Read- 29 février 2024
- Gaëlle MERLIER, Bastien PAVEC
- Life sciences
What is a biosimilar product ? A biosimilar is a biological medicine (i.e., a medicine whose active substance is made by a living organism) highly similar to another already approved biological medicine (the « reference medicine »EMA, [1]) . According to the European Medicines Agency (« EMA »), biosimilar medicines have become major therapeutic...
Read- 23 février 2024
- Philippe PACOTTE, Henri HAGUET
- Employment law - Social welfare law
Digital platforms are major players in our economy and this fact caught the attention of the European institutions. At the heart of their business model is the involvement of platform workers, to whom these companies subcontract all or part of a service. According to Brussels, there are 28 million platform workers in the Member States, 5.5...
Read- 23 février 2024
- Philippe DUMEZ
- Mergers & Acquisitions - Corporate law
Before 2024, there was no uniform federal procedure in the United States for reporting beneficial ownership. As we step into 2024, the Corporate Transparency Act (CTA) comes into effect, requiring a wide range of businesses to disclose their beneficial ownership details to the Financial Crimes Enforcement Network (FinCEN), a division of the...
Read- 22 février 2024
- Anna MILLERET-GODET, Alexandre FRAVAL
- Employment law - Social welfare law
« Every man has two countries : his own and France. » – John F. Kennedy said that to Charles De Gaulle in 1961 while he was in Paris. This is particularly accurate when it comes to employment law. Indeed, Article L. 1321-6 of the French Labor Code provides that any document containing employee obligations or that is necessary for an employee to...
Read- 6 février 2024
- Sébastien POPIJN, Charles PRICE
- Mergers & Acquisitions - Corporate law, Civil and commercial litigation
Share and asset acquisitions can give rise to a series of post-transaction disputes, including claims with regard to alleged breaches in representations and warranties, earn-out provisions, post-closing purchase price adjustments and non-compete provisions. Arbitration is increasingly used to resolve such disputes and arbitration clauses are...
Read